|View printer-friendly version|
|Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials|
Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD
DUBLIN and LAS VEGAS - September 12, 2017 - Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical cohort of the IN.PACT Global Study and four-year results from the pivotal IN.PACT SFA Study were presented in two late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2017 conference in Las Vegas.
IN.PACT Global Study
The data were calculated using Kaplan-Meier survival estimates and revealed a freedom from clinically-driven target lesion revascularization (CD-TLR) rate of 83.3 percent in a real-world patient cohort with a mean lesion length of 12.09 ± 9.54 cm, 18.0 percent in-stent restenosis lesions, 35.5 percent occluded lesions and 39.9 percent diabetes subjects. Additional safety and effectiveness outcomes also included low rates of thrombosis (4.5 percent), occurrences of major target limb amputation (0.7 percent), and CD-TLR (16.9 percent) within two years.
"At two years, the IN.PACT Admiral DCB continues to confirm positive outcomes from the IN.PACT randomized trials, demonstrating efficacy, safety, and durability, despite the complexity of these lesions," said Prof. Zeller. "These results also highlight the clinical utility of the IN.PACT Admiral DCB as a primary therapy in treating patients with some of the most challenging PAD cases."
The IN.PACT Global Study is the largest and most rigorous real-world evaluation of any peripheral artery intervention ever undertaken. It has enrolled over 1,500 patients across 24 countries, including the 1,406 patients in the full clinical cohort presented today, to characterize the performance of the IN.PACT Admiral DCB in treating real-world patients with challenging and complex lesions. The study included adjudication of events by an independent clinical events committee.
IN.PACT SFA Study
Using Kaplan-Meier survival rate estimates, IN.PACT Admiral DCB continued to outperform in freedom from CD-TLR compared to PTA with a 76.8 percent compared to 70.4 in PTA (p= 0.0399). The data also showed the long-term safety benefits of the IN.PACT Admiral DCB, with no major target limb amputations, a low rate of thrombosis, and no major adverse events from years three to four in the IN.PACT Admiral DCB group.
"With the IN.PACT Admiral DCB, pre-clinical studies have demonstrated that the drug remains in the tissue for approximately six months. Therefore, at four years, we would expect to see some catch up effect and at least some late progression of atherosclerosis," said Dr. Schneider. "However, in the four-year data from IN.PACT SFA, we are still seeing sustained durability and clinical benefit. For patients suffering with this chronic condition, these findings are not only encouraging from a therapeutic perspective, but are also suggestive of improved quality of life, with patients requiring fewer reinterventions over time compared to PTA and leaving future treatment options open."
The IN.PACT SFA Trial enrolled 331 patients at 57 sites across Europe and the United States who were randomized to treatment with either the IN.PACT Admiral DCB or PTA. The four-year data includes a total of 284 patients (184 DCB and 103 PTA).
"PAD is a chronic condition associated with disease progression and often requires repeat interventions to manage the disease," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group. "In partnership with the clinical community, our objective has been to develop a safe, effective, and sustainable treatment option for these patients. The data presented today reflects this goal and our commitment to timely and transparent data releases. We are excited to see consistency in real-world patients and fewer interventions out to four years, which was statistically significant."
About IN.PACT Admiral Drug-Coated Balloon
IN.PACT Admiral DCB received the CE (Conformité Européene) Mark in 2009 to treat PAD and was approved by the FDA in December 2014 to treat superficial femoral and popliteal arteries. It has been studied in more than 20 individual clinical trials demonstrating durable safety and clinical benefits. To date, approximately 200,000 patients have been treated with IN.PACT Admiral DCB. It is the only DCB to have published two-year data from a pivotal randomized trial, as well as the first to have presented three- and four-year data.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.